奥浦迈：并购议案获通过 独董陶化安再度投出反对票

Core Viewpoint - The announcement from Aopumai (688293.SH) regarding the resolutions from the 16th meeting of the second board of directors highlights significant disagreements, particularly from independent director Tao Hua'an, who opposed both key proposals related to asset acquisition and fundraising [1] Group 1: Meeting Outcomes - The board meeting was held on November 10, 2025, with all seven directors present [1] - The first proposal regarding the issuance of shares and cash for asset acquisition was approved with a vote of 6 in favor, 1 against, and 0 abstentions [1] - Independent director Tao Hua'an cast the only dissenting vote, stating that the company currently does not have a necessity for acquisitions [1] - The second proposal, related to fundraising, was passed with 6 votes in favor, 0 against, and 1 abstention [1] - Tao Hua'an also abstained from the second proposal for the same reasons as the first [1] Group 2: Proposal Details - The revisions to the proposals were prompted by the completion of asset valuation work by the appraisal agency on the identifiable net assets of the target company, Pengli Bio [1] - The company incorporated further review comments from the Shanghai Stock Exchange into the proposals [1] - Prior to the board meeting, the proposals had already been reviewed by the company's strategic committee, audit committee, and a special meeting of independent directors, and were authorized by the company's first extraordinary general meeting of 2025, thus not requiring further shareholder approval [1]